Physician profile
Debra Berry
NPI 1952412603
$1,602.42
in general payments reported to CMS, 2019-2025
23 companies · $300 in 2025
The $300 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $124 · 2021: $257 · 2022: $122 · 2023: $254 · 2024: $416 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877 · Long Term Medical Supply Or Device Loan: $93.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.21 |
| Long Term Medical Supply Or Device Loan | $93.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $176.35 | 2019-2023 | |
| Cranial Technologies, INC | $154.58 | 2020-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $150.93 | 2021-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $146.32 | 2024-2025 | |
| Pfizer INC. | $123.54 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.20 | 2021-2024 | |
| Kaleo, INC. | $106.90 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $103.07 | 2019-2021 | |
| Baxter Healthcare | $93.31 | 2024 | Hillrom - Spot Vision Screener |
| Corium, LLC | $74.50 | 2024-2025 | Azstarys |
| Welch Allyn | $66.36 | 2020 | |
| Collegium Pharmaceutical, INC. | $51.59 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $39.15 | 2023 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $29.37 | 2019 | |
| Mylan Pharmaceuticals INC. | $27.74 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $22.90 | 2025 | Nexplanon |
| Acadia Pharmaceuticals INC | $19.34 | 2024 | Daybue |
| Tempus Ai, INC | $18.95 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.97 | 2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $17.07 | 2019 | |
| Exeltis, USA INC. | $17.03 | 2023 | Slynd |
| Adlon Therapeutics L.P. | $16.25 | 2020 | |
| Biomerieux INC | $16.00 | 2025 | Biofire Spotfire Control Station |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.